Is Long-Term Proton Pump Inhibitor Use a Cause of Leaky Gut Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-04

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our study aims to investigate the effect of bacterial overgrowth induced by long-term PPI use on zonulin levels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Proton Pump Inhibitor of Daily Use for One Month on Kidney Function Test

NCT04022837

Proton Pump Inhibitor Allergy

UNKNOWN PHASE2

Effect of Daily Use Proton Pump Inhibitors for One Month on Kidney Function

NCT03910647

Proton Pump Inhibitor Allergy

UNKNOWN PHASE2

PPI and Microbiome in Healthy Volunteers and Functional Dyspepsia

NCT03545243

Dysbiosis

COMPLETED PHASE4

Importance of Cytokines in Peptic Ulcer Disease: Implications for Treatment

NCT00534443

Peptic Ulcer

COMPLETED PHASE4

Efficacy of Low Dose of Proton Pump Inhibitor in Treatment Bleeding Ulcers

NCT03163680

Gastroduodenal Ulcer Marginal Ulcer Peptic Ulcer Hemorrhage

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study included a total of 75 participants, with 45 individuals classified as long-term PPI users and 30 as non-PPI users. The PPI user group was defined as those who had been consistently using PPIs (specifically omeprazole, lansoprazole, pantoprazole, esomeprazole, or rabeprazole) on a daily basis for a minimum of 6 months or at least twice a week for a minimum of 2 years. The control group comprised individuals who had never used PPIs. Venous blood samples were taken from all participants to measure serum zonulin levels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Proton Pump Inhibitor Adverse Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel Assignment

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Using PPI

Group receiving a long-term PPI (omeprazole, lansoprazole, pantoprazole, esomeprazole and rabeprazole) every day for at least 6 months or at least twice a week for at least 2 years.

Group Type EXPERIMENTAL

Blood for zonulin level was drawn from the group.

Intervention Type DIAGNOSTIC_TEST

Serum zonulin levels were determined by taking 5 cc blood from the antebrachial veins of the patients.

Control

A control group was formed from individuals who had never used PPI.

Group Type EXPERIMENTAL

Blood for zonulin level was drawn from the group.

Intervention Type DIAGNOSTIC_TEST

Serum zonulin levels were determined by taking 5 cc blood from the antebrachial veins of the patients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood for zonulin level was drawn from the group.

Serum zonulin levels were determined by taking 5 cc blood from the antebrachial veins of the patients.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The patient group was patients taking long-term PPIs (omeprazole, lansoprazole, pantoprazole, esomeprazole and rabeprazole) every day for at least 6 months or at least twice a week for at least 2 years.

A control group was formed from individuals who had never used PPI.

Exclusion Criteria

Those with inflammatory bowel disease, celiac disease, type 1 diabetes, active gastroenteritis, acute kidney failure, chronic kidney failure, and those who had used antibiotics for any reason in the last 3 months, as well as those receiving probiotic drug support, were not included in the study

\-

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes